{"title":"Browse all our reports","description":"","products":[{"product_id":"user-guide-venture-capital-biotech","title":"The STAT user’s guide to venture capital in biotech","description":"\u003cp\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003ePublished: Oct. 2019\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eThis 140-page report profiles over 50 venture capital firms that invest in biotechnology — from firms that specialize in biotech (or in health care in general), to generalists who are pumping money into the broader technology sector, with biotech as part of the mix. This is an ideal report for startups looking to raise venture capital, and to navigate the field of opportunity from coast to coast.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eHighlights include:\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNine deep dives into venture capital companies that help paint a picture of the biotech investing process — from the research itself, to how the investors met the inventors, to how the deals got built.\u003c\/li\u003e\n\u003cli\u003eInsight into some of the companies that have received investment funds from these firms.\u003c\/li\u003e\n\u003cli\u003eGeographically organized portraits of other venture capital companies investing in the space, including details about the types of investments each firm makes, their leadership team, and their areas of interest.\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eAfterword and analysis by Matthew Herper, STAT senior writer\u003c\/span\u003e\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\" mce-data-marked=\"1\"\u003e\u003cspan mce-data-marked=\"1\"\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\" mce-data-marked=\"1\"\u003e\u003cspan mce-data-marked=\"1\"\u003eTake a peek at what's included in this report.\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv id=\"DV-viewer-6458276-STAT-Report-User-Guide-Venture-Capital-Biotech\" class=\"DC-embed DC-embed-document DV-container\"\u003e\u003c\/div\u003e\n\u003cscript src=\"\/\/assets.documentcloud.org\/viewer\/loader.js\"\u003e\u003c\/script\u003e \u003cscript\u003e\/\/ \u003c![CDATA[\nDV.load(\"https:\/\/www.documentcloud.org\/documents\/6458276-STAT-Report-User-Guide-Venture-Capital-Biotech.js\", {\n  responsive: true,\n    height: 600,\n    sidebar: false,\n    text: false,\n    pdf: false,\n    container: \"#DV-viewer-6458276-STAT-Report-User-Guide-Venture-Capital-Biotech\"\n  });\n\/\/ ]]\u003e\u003c\/script\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":30268381200487,"sku":"rid_1-1","price":995.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":30268381233255,"sku":"rid_1-2","price":4975.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Oct2019-MetaImage.png?v=1702404855"},{"product_id":"company-license-stat-user-guide-venture-capital-in-biotech","title":"Company License: The STAT user’s guide to venture capital in biotech","description":"\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eThis 140-page report profiles over 50 venture capital firms that invest in biotechnology — from firms that specialize in biotech (or in health care in general), to generalists who are pumping money into the broader technology sector, with biotech as part of the mix. This is an ideal report for startups looking to raise venture capital, and to navigate the field of opportunity from coast to coast.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eHighlights include:\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNine deep dives into venture capital companies that help paint a picture of the biotech investing process — from the research itself, to how the investors met the inventors, to how the deals got built.\u003c\/li\u003e\n\u003cli\u003eInsight into some of the companies that have received investment funds from these firms.\u003c\/li\u003e\n\u003cli\u003eGeographically organized portraits of other venture capital companies investing in the space, including details about the types of investments each firm makes, their leadership team, and their areas of interest.\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eAfterword and analysis by Matthew Herper, STAT senior writer\u003c\/span\u003e\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\" mce-data-marked=\"1\"\u003e\u003cspan mce-data-marked=\"1\"\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\" mce-data-marked=\"1\"\u003e\u003cspan mce-data-marked=\"1\"\u003eTake a peek at what's included in this report.\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv id=\"DV-viewer-6458276-STAT-Report-User-Guide-Venture-Capital-Biotech\" class=\"DC-embed DC-embed-document DV-container\"\u003e\u003c\/div\u003e\n\u003cscript src=\"\/\/assets.documentcloud.org\/viewer\/loader.js\"\u003e\u003c\/script\u003e \u003cscript\u003e\/\/ \u003c![CDATA[\nDV.load(\"https:\/\/www.documentcloud.org\/documents\/6458276-STAT-Report-User-Guide-Venture-Capital-Biotech.js\", {\n  responsive: true,\n    height: 600,\n    sidebar: false,\n    text: false,\n    pdf: false,\n    container: \"#DV-viewer-6458276-STAT-Report-User-Guide-Venture-Capital-Biotech\"\n  });\n\/\/ ]]\u003e\u003c\/script\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"License","offer_id":31086052999271,"sku":"rid_1-1","price":1696.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/products\/report-1-img_4e49a797-4888-4733-8a10-226d8ffefec3.jpg?v=1572554487"},{"product_id":"stat-guide-to-viral-vectors-the-linchpin-of-gene-therapy","title":"The STAT guide to viral vectors, the linchpin of gene therapy","description":"\u003cp\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003ePublished: Dec. 2019\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eGene therapies were once dismissed as too dangerous to introduce to the treatment landscape. But today they are making a comeback with hundreds of products in the pipeline and under trial. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eIn this report, we dive into the science, and business, of viral vector technologies. We spoke with executives from 18 companies to identify the pipeline of therapies that are nearing the clinic, the engineering and production challenges that may stifle progress, and how key players are looking to overcome those challenges. Our aim: to make the problems, stakes, and possibilities clear to everyone — whether you’re an executive, investor, or policymaker actively working in the space, or patients and families interested in learning more. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cstrong\u003eHighlights include\u003c\/strong\u003e:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eAn overview of the basic science behind viral vectors, and the history of their development\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eMajor challenges in the development, manufacturing, and testing of viral vectors — and possible solutions\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eCase studies of therapies in eight disease categories that are advancing through preclinical studies, or that are already being tested in clinical trials\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eAnalysis of the U.S. Food and Drug Administration’s approach to regulating viral vector therapies\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003cdiv id=\"DV-viewer-6572293-STAT-Report-Guide-Viral-Vectors-Preview\" class=\"DC-embed DC-embed-document DV-container\"\u003e\u003c\/div\u003e\n\u003cscript src=\"\/\/assets.documentcloud.org\/viewer\/loader.js\"\u003e\u003c\/script\u003e \u003cscript\u003e\/\/ \u003c![CDATA[\nDV.load(\"https:\/\/www.documentcloud.org\/documents\/6572293-STAT-Report-Guide-Viral-Vectors-Preview.js\", {\n  responsive: true,\n    height: 600,\n    sidebar: false,\n    text: false,\n    pdf: false,\n    container: \"#DV-viewer-6572293-STAT-Report-Guide-Viral-Vectors-Preview\"\n  });\n\/\/ ]]\u003e\u003c\/script\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":31609491882087,"sku":"rid_3-1","price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":31609491914855,"sku":"rid_3-2","price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Dec2019-MetaImage.png?v=1702404763"},{"product_id":"biosimilars-what-will-it-take-to-deliver-on-their-promise","title":"Biosimilars: What will it take to deliver on their promise?","description":"\u003cp\u003e\u003cem\u003ePublished: Jan. 2020\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eBiosimilars — nearly identical versions of biologic drugs — have been heralded as a salve for the skyrocketing costs of prescription medications used to treat a wide variety of diseases. But so far they have been a disappointment.\u003cbr\u003eIn this STAT Report, we dive into the legal, manufacturing, and regulatory challenges that biosimilars currently face — and the possible solutions that could help biosimilars deliver on their promise. This vital read will help people in industry, academia, and politics understand the complex world of biosimilars and take the measure of what might be done to ensure that they are worthwhile to both patients and businesses alike.\u003c\/p\u003e\n\u003cdiv id=\"DV-viewer-6572293-STAT-Report-Guide-Viral-Vectors-Preview\" class=\"DC-embed DC-embed-document DV-container\"\u003e\u003c\/div\u003e\n\u003cdiv id=\"DV-viewer-6672677-STAT-Report-Biosimilars-Preview\" class=\"DC-embed DC-embed-document DV-container\"\u003e\u003c\/div\u003e\n\u003cscript src=\"\/\/assets.documentcloud.org\/viewer\/loader.js\"\u003e\u003c\/script\u003e \u003cscript\u003e\/\/ \u003c![CDATA[\n  DV.load(\"https:\/\/www.documentcloud.org\/documents\/6672677-STAT-Report-Biosimilars-Preview.js\", {\n  responsive: true,\n    height: 600,\n    sidebar: false,\n    text: false,\n    pdf: false,\n    container: \"#DV-viewer-6672677-STAT-Report-Biosimilars-Preview\"\n  });\n\/\/ ]]\u003e\u003c\/script\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":31866358366311,"sku":"rid_3-1","price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":31866358399079,"sku":"rid_3-2","price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Jan2020-Biosimilars-MetaImage.png?v=1694195384"},{"product_id":"stat-guide-interpreting-clinical-trial-results","title":"STAT’s guide to interpreting clinical trial results","description":"\u003cp\u003e\u003cem\u003ePublished: Mar. 2020\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eInterpreting clinical trial results is not for the faint of heart. Companies spin, short-sellers hawk, and everyone else is left swimming through the muck. But there is an art to reading, and writing, scientific results — and you can learn it.\u003cbr\u003e\u003cbr\u003eIn this report, STAT senior writers \u003ca href=\"https:\/\/www.statnews.com\/staff\/sharon-begley\/\" target=\"_blank\"\u003eSharon Begley\u003c\/a\u003e and \u003ca href=\"https:\/\/www.statnews.com\/staff\/adam-feuerstein\/\" target=\"_blank\"\u003eAdam Feuerstein\u003c\/a\u003e provide basic tools to help you read clinical trial results with an appropriately skeptical (or at least critical) eye. They also examine specific examples of spin, noting the sections of papers reporting the results of clinical trials where they appear — and why that matters. If you’re looking to cut through noise to better understand scientific data or make sense of company performance and value, this report will give you the foundation you need to make smarter business decisions. \u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cstrong\u003eHighlights include\u003c\/strong\u003e:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli style=\"font-weight: 400;\"\u003eA definition of spin in clinical trials, supported by real life examples.\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\"\u003eFour key questions to ask when evaluating clinical trial results, and an overview of additional tools you need to read results more critically\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\"\u003eAnalysis of the red flags you should look for in clinical trial design, execution, and reporting of results.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cdiv class=\"DC-embed DC-embed-document DV-container\" id=\"DV-viewer-6812480-STAT-Report-Interpreting-Clinical-Trials\"\u003e\u003cem\u003e\u003cstrong\u003eYou can find the updated version of this report from 2023 \u003ca href=\"https:\/\/reports.statnews.com\/products\/stat-guide-interpreting-clinical-trials-update\"\u003ehere\u003c\/a\u003e. \u003c\/strong\u003e\u003c\/em\u003e\u003c\/div\u003e\n\u003cscript src=\"\/\/assets.documentcloud.org\/viewer\/loader.js\"\u003e\u003c\/script\u003e \u003cscript\u003e\n  DV.load(\"https:\/\/www.documentcloud.org\/documents\/6812480-STAT-Report-Interpreting-Clinical-Trials.js\", {\n  responsive: true,\n    height: 600,\n    sidebar: false,\n    text: false,\n    pdf: false,\n    container: \"#DV-viewer-6812480-STAT-Report-Interpreting-Clinical-Trials\"\n  });\n\u003c\/script\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":32071781318759,"sku":"rid_3-1","price":49.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":32071781384295,"sku":"rid_3-2","price":245.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Mar2020-MetaImage.png?v=1702404719"},{"product_id":"the-20-executives-and-companies-to-know-in-chinese-biotech","title":"The 20 Executives — and Companies — to Know in Chinese Biotech","description":"\u003cp\u003e\u003cem\u003ePublished: June 2020\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eIn China, biotechnology long lagged behind the industry in the West. Now, thanks to billions of dollars in state and private investment — and dramatic regulatory changes — what took a half century of iteration in the U.S. has happened over the course of about 20 years in China. The results are astounding, with China now developing treatments and generics that rival the best efforts of the drug industry’s incumbents. \u003c\/p\u003e\n\u003cp\u003eIn this report, a collaboration between STAT and The Wire, a news and data analytics company focused on China, we feature the 20 most important executives leading this revolution in Chinese drug development. Their stories track China's evolution in the global market for new therapies. And, as a result, this report helps tell the story of some of the industry’s hottest companies.\u003c\/p\u003e\n\u003cp\u003eHighlights include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\n\u003cb\u003eA brief overview\u003c\/b\u003e\u003cspan style=\"font-weight: 400;\"\u003e of the growth of China’s biotech industry\u003c\/span\u003e\u003cb\u003e \u003c\/b\u003e\n\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\n\u003cb\u003eProfiles\u003c\/b\u003e\u003cspan style=\"font-weight: 400;\"\u003e of 20 of the most important Chinese biotech executives\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\n\u003cb\u003eSnapshots\u003c\/b\u003e\u003cspan style=\"font-weight: 400;\"\u003e of their companies -- including annual revenue and market cap\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003cdiv id=\"DV-viewer-6889536-STAT-Report-the-20-Executives-and-Companies-to\" class=\"DC-embed DC-embed-document DV-container\"\u003e\u003c\/div\u003e\n\u003cscript src=\"\/\/assets.documentcloud.org\/viewer\/loader.js\"\u003e\u003c\/script\u003e \u003cscript\u003e\n  DV.load(\"https:\/\/www.documentcloud.org\/documents\/6889536-STAT-Report-the-20-Executives-and-Companies-to.js\", {\n  responsive: true,\n    height: 600,\n    sidebar: false,\n    text: false,\n    pdf: false,\n    container: \"#DV-viewer-6889536-STAT-Report-the-20-Executives-and-Companies-to\"\n  });\n\u003c\/script\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":32356899553383,"sku":"","price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":32356899586151,"sku":"","price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Jun2020-MetaImage.png?v=1702404679"},{"product_id":"ranking-biotechs-top-venture-capital-firms","title":"2020 Edition: Ranking biotech's top venture capital firms","description":"\u003cp\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003ePublished: July 2020\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eWhich venture capital firms get the best returns? STAT’s Kate Sheridan did some digging and has a definitively ranked list for more than a dozen of the biggest names in biotech investment: including Third Rock Ventures, OrbiMed, ARCH Venture Partners, and even Flagship Pioneering. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eFor this 50-page STAT Report, she combed through returns data — normally private, now made available through Freedom of Information Act requests and certain public records. Alongside a ranking of the firms that are most relevant to biotech investors, she’s also included a deep dive into each firm on the list — explaining the strategies behind their performance, the drugs and companies in which they’ve invested, and the people who are making key decisions.\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eExplore the 2021 update to this report \u003ca href=\"https:\/\/reports.statnews.com\/products\/2021-ranking-biotechs-top-venture-capital-firms\"\u003ehere\u003c\/a\u003e.\u003c\/p\u003e\n\u003cul\u003e\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cdiv id=\"DV-viewer-6997891-STAT-JulyReport-Preview\" class=\"DC-embed DC-embed-document DV-container\"\u003e\u003c\/div\u003e\n\u003cscript src=\"\/\/assets.documentcloud.org\/viewer\/loader.js\"\u003e\u003c\/script\u003e \u003cscript\u003e\/\/ \u003c![CDATA[\nDV.load(\"https:\/\/www.documentcloud.org\/documents\/6997891-STAT-JulyReport-Preview.js\", {\n  responsive: true,\n    container: \"#DV-viewer-6997891-STAT-JulyReport-Preview\"\n  });\n\/\/ ]]\u003e\u003c\/script\u003e \u003cnoscript\u003e\n  \u0026lt;a href=\"https:\/\/www.documentcloud.org\/documents\/6997891\/STAT-JulyReport-Preview.pdf\"\u0026gt;STAT JulyReport Preview (PDF)\u0026lt;\/a\u0026gt;\n  \u0026lt;br\u0026gt;\n  \u0026lt;a href=\"https:\/\/www.documentcloud.org\/documents\/6997891\/STAT-JulyReport-Preview.txt\"\u0026gt;STAT JulyReport Preview (Text)\u0026lt;\/a\u0026gt;\n\u003c\/noscript\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":32677107859559,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":32677107892327,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/VCFirms-Jul2020-MetaImage.png?v=1694194797"},{"product_id":"reports-package","title":"STAT Reports Package","description":"\u003cp\u003e \u003c\/p\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cp\u003e\u003cspan\u003eAdd this reports package to your cart, and then complete the checkout process. Once you have, you'll receive an email with instructions for downloading the full report file(s). This report is digital-only (PDF), so you will not receive a printout.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e","brand":"STAT Reports","offers":[{"title":"License","offer_id":32766021140583,"sku":null,"price":3500.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/products\/AdobeStock_172021633.jpg?v=1597952153"},{"product_id":"license-upgrade","title":"License Upgrade - normal reports","description":"\u003cp\u003e \u003c\/p\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cp\u003e\u003cspan\u003eAdd this reports package to your cart, and then complete the checkout process. This price covers the difference between an individual and a group license for a STAT Report. Once you have completed purchase, you'll be able to share the full report file you have previously received with your team. This report is digital-only (PDF), so you will not receive a printout.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e","brand":"STAT Reports","offers":[{"title":"License","offer_id":32769282900071,"sku":null,"price":250.0,"currency_code":"USD","in_stock":true},{"title":"Group license - STAT's guide to clinical trials","offer_id":39258889814119,"sku":"","price":25.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/products\/AdobeStock_172021633_7ac13d75-dde5-4d44-ac71-d5c3766e6673.jpg?v=1598038869"},{"product_id":"the-emerging-role-of-remote-patient-monitoring","title":"The Emerging Role of Remote Patient Monitoring","description":"\u003cp\u003e\u003cem\u003ePublished: Sep. 2020\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eAs health care grows increasingly virtual, a shift accelerated by the Covid-19 pandemic, tech giants and startups alike are racing to stake out their territory, rapidly developing tools that can monitor health — or even diagnose disease — from a distance. But regulators are struggling to keep pace with technological advances, and remote patient monitoring still faces significant obstacles to reach its market potential.\u003c\/p\u003e\n\u003cp\u003eIn this report, we explore how a new class of patient-consumer is driving change in RPM, analyze the business models of companies moving into the space, and examine what the future of the field could look like. We’ll also bring you perspectives from the leaders of some of the sector’s most promising and prominent companies, including Apple, Fitbit, Omada Health, Onduo, and Propeller Health.\u003c\/p\u003e\n\u003cul\u003e\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cdiv id=\"DV-viewer-7208937-STAT-Reports-the-Emerging-Role-of-Remote-Patient\" class=\"DC-embed DC-embed-document DV-container\"\u003e\u003c\/div\u003e\n\u003cscript src=\"\/\/assets.documentcloud.org\/viewer\/loader.js\"\u003e\u003c\/script\u003e \u003cscript\u003e\n  DV.load(\"https:\/\/www.documentcloud.org\/documents\/7208937-STAT-Reports-the-Emerging-Role-of-Remote-Patient.js\", {\n  responsive: true,\n    container: \"#DV-viewer-7208937-STAT-Reports-the-Emerging-Role-of-Remote-Patient\"\n  });\n\u003c\/script\u003e \u003cnoscript\u003e\n  \u003ca href=\"https:\/\/assets.documentcloud.org\/documents\/7208937\/STAT-Reports-the-Emerging-Role-of-Remote-Patient.pdf\"\u003eSTAT Reports the Emerging Role of Remote Patient Monitoring Preview (PDF)\u003c\/a\u003e\n  \u003cbr\u003e\n  \u003ca href=\"https:\/\/assets.documentcloud.org\/documents\/7208937\/STAT-Reports-the-Emerging-Role-of-Remote-Patient.txt\"\u003eSTAT Reports the Emerging Role of Remote Patient Monitoring Preview (Text)\u003c\/a\u003e\n\u003c\/noscript\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":32831604260967,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":32831604293735,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Sep2020-MetaImage.png?v=1702404630"},{"product_id":"nanotechnology-in-medicine","title":"Nanotechnology in Medicine","description":"\u003cp\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003ePublished: Dec. 2020\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eI\u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003ef you’ll pardon the pun, nanotechnology is big. The science of manipulating molecules and materials under 100 nanometers in size is spurring advances in drug development, diagnosis, and treatment. Since 1970, more than 600 applications have been filed with the Food and Drug Administration to test drug products containing nanomaterials. Of those products, 19 have been approved.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eIn this latest STAT report, we take a look at the key companies involved in bringing nano-products to market; the challenges they’re facing in demonstrating safety and efficacy; and the ways they’re trying to overcome them. We also examine the different kinds of nanomaterials being developed for medical applications, how they work, and the treatments in which they are being used. If you have an interest in future directions of drug development and delivery, vaccines, and imaging, this report is for you.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/20415918-stat-report-nanotech_in_medicine_preview\/?embed=1\u0026amp;title=1\" title=\"STAT-Report-Nanotech_in_Medicine_preview (Hosted by DocumentCloud)\" width=\"600\" height=\"905\" style=\"border: 1px solid #aaa;\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":33033260367975,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":33033260400743,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Dec2020-MetaImage.png?v=1702404583"},{"product_id":"understanding-synthetic-biology","title":"Understanding synthetic biology, featuring 10 companies to watch","description":"\u003cp\u003e\u003cem\u003ePublished: Feb. 2021\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eSynthetic biology is not a new field. But it’s moving at warp speed thanks to advances in machine learning, artificial intelligence, and automation. Investment in companies working in this field are rapidly expanding, with the industry receiving \u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003e$7.8 billion in private and public financing in 2020 — nearly 2 1\/2 times the amount poured into the industry in 2019. This report will help you develop a deeper understanding of synthetic biology and key players. In addition to explaining the tools at the heart of synthetic biology, the report offers a closer look at 10 companies taking the field by storm, including bit.bio, Synlogic, Twist Biosciences, eGenesis, and Strateos.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003ciframe style=\"border: 1px solid #aaa;\" title=\"STAT-SyntheticBiology-Report Preview (Hosted by DocumentCloud)\" src=\"https:\/\/embed.documentcloud.org\/documents\/20489951-stat-syntheticbiology-report-preview\/?embed=1\u0026amp;title=1\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\" width=\"700\" height=\"905\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":33190867632231,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":33190867664999,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Feb2021-MetaImage.png?v=1702404539"},{"product_id":"good-bacteria","title":"Good bacteria: The microbiome, its vast therapeutic potential, and the challenges ahead","description":"\u003cp\u003e\u003cem\u003ePublished: April 2021\u003cbr\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003eIn the late 1950s a radical idea was born: What if a patients’ gastrointestinal inflammation could be cured by implanting a healthier gut? The result, now known as a fecal microbiota transplant, is the foundation of the microbiome industry. While the field is still in its commercial infancy, it is showing promise — companies like \u003c\/span\u003e\u003cb data-mce-fragment=\"1\"\u003eSeres Therapeutics\u003c\/b\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003e, \u003c\/span\u003e\u003cb data-mce-fragment=\"1\"\u003eRebiotix\u003c\/b\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003e, and \u003c\/span\u003e\u003cb data-mce-fragment=\"1\"\u003eFinch Therapeutics\u003c\/b\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003e are already presenting mid- and late-stage clinical trial data for their live biotherapeutic products, and several others have successfully completed early-stage human studies.\u003c\/span\u003e\n\u003cp\u003e\u003cbr data-mce-fragment=\"1\"\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003eThis report examines the science behind this nascent industry, fleshing out what we know about the ecology of the human microbiome and the various interventions scientists are studying to help keep or make it healthy. It also looks at the vast array of conditions that microbiome companies are hoping to treat, and the challenges that these biotechs face in research, manufacturing, regulation and ultimately bringing these treatments to the clinic.\u003c\/span\u003e \u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/20659779-stat-good-bacteria-report-preview\/?embed=1\u0026amp;title=1\" title=\"STAT Good Bacteria Report Preview (Hosted by DocumentCloud)\" style=\"border: 1px solid #aaa;\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\" width=\"700\" height=\"905\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":39319917690983,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":39319917723751,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Apr2021-MetaImage.png?v=1702404482"},{"product_id":"antibiotic-drug-pipeline","title":"The revitalization of the antibiotic drug pipeline","description":"\u003cp\u003e\u003cem\u003ePublished: June 2021\u003cbr\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003e\u003c\/span\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003eIn 2016, a landmark report on the global problem of antibiotic resistance issued a dire warning was issued: “It is fair to assume that over 1 million people will have died from antimicrobial resistance since I started this review in the summer of 2014,” wrote former Goldman Sachs economist Jim O’Neill, who authored the report. “As well as these tragic human costs, antimicrobial resistance also has a very real economic cost, which will continue to grow if resistance is not tackled. The cost in terms of lost global production between now and 2050 would be an enormous $100 trillion if we do not take action.” \u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003eFive years later, though, the prognosis remains sobering. And the threat is all the more recognizable coming off the heels of our most recent Covid-19 pandemic. Now, with renewed scientific attention being paid to other emerging pathogens — including antibiotic-resistant superbugs — our latest STAT Report explores the factors that have led to the rise of antimicrobial resistance in recent years. It also considers the critical shortcomings in the research and development of novel antibiotic drugs to tackle this resistance, and the solutions for closing that gap.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003eWe hope this report will be of intense interest to readers who want to understand how medicine, science, and public policy intersect in the complex world of antibiotic resistance. It is grounded in months of comprehensive reporting, and takes the measure of a topic that is increasingly vital to people in industry, academia, and politics.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/20945974-stat-antiobiotic-pipeline-report-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" title=\"STAT Antiobiotic Pipeline Report Preview (Hosted by DocumentCloud)\" style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" width=\"700\" height=\"905\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":39378295062631,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":39378295095399,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Jun2021-MetaImage.png?v=1702404434"},{"product_id":"2021-ranking-biotechs-top-venture-capital-firms","title":"2021 Update: Ranking biotech's top venture capital firms","description":"\u003cp\u003e\u003cem\u003ePublished: Aug. 2021\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eLast year, STAT’s Kate Sheridan filed numerous Freedom of Information Act requests and combed through private returns data for more than a dozen of the biggest names in biotech venture capital. The resulting report — which profiled these firms and their executives, explained the strategies and companies behind their performance, and ranked them based on who delivered the best returns to shareholders — was one of our most popular STAT Reports to date. \u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eOur latest STAT Report is an update of the classic, this time with 2020 data. It features some jaw-dropping numbers from behemoths like Flagship Pioneering, some surprising shakeups, and a few new “faces” — including Lilly Asia Ventures and Mission BioCapital.\u003c\/p\u003e\n\u003cp\u003eReview the 2020 edition of this report \u003ca href=\"https:\/\/reports.statnews.com\/products\/ranking-biotechs-top-venture-capital-firms\"\u003ehere\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\" data-mce-style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003cp\u003e\u003ciframe style=\"border: 1px solid #aaa;\" title=\"STAT Ranking Biotech's VC Firms - 2021 Update Preview (Hosted by DocumentCloud)\" src=\"https:\/\/embed.documentcloud.org\/documents\/21045170-stat-ranking-biotechs-vc-firms-2021-update-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\" width=\"700\" height=\"905\"\u003e\u003c\/iframe\u003e\u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":39440637100135,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":39440637132903,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/VCFirms-Aug2021-MetaImage.png?v=1694195013"},{"product_id":"the-shroom-boom","title":"The ‘shroom boom’: The meteoric rise of the psychedelic medicine industry","description":"\u003cp\u003e\u003cem\u003ePublished: Oct. 2021\u003c\/em\u003e\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003eOver the past 18 months, while most of us were distracted by the pandemic, the psychedelic industry exploded. Companies that had for years quietly pursued research and recruited investors went public. Dozens of startups launched. And venture capitalists began to pay serious attention. \u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003eAn industry that a year ago had a market cap of less than $1B suddenly housed four companies that each individually had a billion-dollar valuation. \u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003eThe potential of the psychedelics industry has never been bigger. Long-stigmatized drugs like esketemine, MDMA and psilocybin are advancing rapidly through clinical trials for treatments of a range of mental health conditions, and one in four people suffer from mental health disorders. But some serious barriers lie in the way. Our latest report, written by STAT’s Olivia Goldhill, explores the opportunities for growth in this nascent industry — and the regulations and patenting barriers that could stymie profit.   \u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\" data-mce-style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003cp\u003e\u003ciframe style=\"border: 1px solid #aaa;\" title=\"STAT Shroom Boom Report Preview (Hosted by DocumentCloud)\" src=\"https:\/\/embed.documentcloud.org\/documents\/21088488-stat-shroom-boom-report-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" width=\"600\" height=\"905\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e\u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":39509576384615,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":39509576417383,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Oct2021-MetaImage.png?v=1702404322"},{"product_id":"continuous-glucose-monitoring","title":"Continuous glucose monitoring: how it's advancing diabetes care","description":"\u003cp\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003ePublished: January 2022\u003cbr\u003e\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003eGone are the days where a type 1 diabetes diagnosis meant a lifetime of finger pricking and injections. Today, almost half of the 4 million Americans living with type 1 diabetes use devices called continuous glucose monitors, or CGMs, to monitor their glucose levels and regulate their insulin levels in real-time.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003eWhile uptake of CGM so far has been concentrated in the care of people with type 1 diabetes, CGMs are increasingly being prescribed to a much larger group – those 40 million plus Americans living with type 2 diabetes. And, as the market for CGMs grows — to a $5 billion market in 2021, by some estimates — so  too does the optimism that they will help manage the flood of unmanaged type 2 diabetes. \u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003eIn our latest report, written by STAT’s Katie Palmer, we’ve gathered our best intelligence on the burgeoning industry of CGM, and where it’s likely to head next. \u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/21175227-stat-cgm-report-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" title=\"STAT CGM Report Preview\" style=\"border: 1px solid #aaa;\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\" width=\"600\" height=\"905\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":39592272167015,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":39592272199783,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Jan2020-Biosimilars-MetaImage_2c3409bd-7d56-4c37-919d-aaf0973ab981.png?v=1694195883"},{"product_id":"speed-and-safety-fdas-drug-approval","title":"The need for speed and safety: A primer on the FDA's drug approval pathways","description":"\u003cp\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003ePublished: May 2022\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eAt the heart of the Food and Drug Administration’s work on drugs are some deceptively simple questions: Does the medicine in question provide a benefit for patients that outweighs its risks? Will the medicine at least keep the disease from progressing? Can doctors and patients believe the FDA has made the right call in approving this drug?\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eThe FDA's traditional approval process involves a series of rigorous clinical trials that can take as long as a decade to set up, oversee, and evaluate. The agency has become more flexible with this standard, especially in cases where medicines may help people facing fatal or debilitating diseases. Now, however, some of the ways the FDA speeds up the drug approval process, like accelerated approval and fast-track designations, are coming under increasing scrutiny. \u003c\/span\u003e\u003cbr\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eOur latest report unpacks the differences between the different ways the FDA approves drugs, like accelerated approvals, fast-track designations, and emergency use authorizations. \u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003e. It touches on how we got here, where the agency is headed next, and what's at stake as those standards shift and change.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cul\u003e\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003ciframe style=\"border: 1px solid #aaa;\" width=\"600\" height=\"905\" title=\"STAT FDA Primer Report Preview (Hosted by DocumentCloud)\" src=\"https:\/\/embed.documentcloud.org\/documents\/22008632-stat-fda-primer-report-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":39715597287527,"sku":null,"price":199.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":39715597320295,"sku":null,"price":955.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/May2022-MetaImage.png?v=1702404180"},{"product_id":"race-for-longevity","title":"The race for longevity: How scientists — and industry — are seeking to extend healthy lives","description":"\u003cp\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003ePublished: August 2022\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003e\u003c\/span\u003e\u003cspan style=\"font-weight: 400;\" data-mce-fragment=\"1\" data-mce-style=\"font-weight: 400;\"\u003eIn the early 1990s, biologist Cynthia Kenyon discovered that an alteration to a single gene of a tiny, transparent worm could double the creature’s lifespan. The discovery spawned the field of longevity research, sending scientists chasing after the biochemical secrets that long-lived species like bowhead whales and naked mole rats carry coiled within their cells. \u003cbr data-mce-fragment=\"1\"\u003e\u003cbr data-mce-fragment=\"1\"\u003eThis report first examines the science behind this nascent industry, exploring what we know about the biology of aging and the various types of interventions scientists are studying to help slow or even reverse its corrosive effects. Then, we present the leading companies in the space right now and the status of their drug development efforts. We’ll look too, at the vast array of age-related conditions that these companies are hoping to treat at their root cause. Lastly, this report considers the need for such developments. Our aim is to make the problems, stakes, and possibilities clear to everyone.\u003cbr data-mce-fragment=\"1\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/22127731-stat-report-17-longevity_preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" title=\"STAT Longevity Report preview (Hosted by DocumentCloud)\" width=\"700\" height=\"905\" style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":39820067405927,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":39820067471463,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Aug2022-MetaImage.png?v=1702404278"},{"product_id":"2022-ranking-biotechs-top-venture-capital-firms","title":"2022 Update: Ranking biotech's top venture capital firms","description":"\u003cp\u003e\u003cem\u003ePublished: Aug. 2022\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eWhich venture capital firms get the best returns? Our latest STAT Report is an update of our most popular report to date, this time with 2021 data. In it, STAT’s Kate Sheridan provides a definitively ranked list of more than a dozen of the biggest names in biotech investment, including Third Rock Ventures, OrbiMed, ARCH Venture Partners, and Flagship Pioneering.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-renderer-start-pos=\"703\"\u003eThis report — the third in as many years — attempts to dig a little deeper into venture capital firms, to tease out not just which firms were best positioned before the downturn, but to look at which ones have made the best bets on the fledgling companies in which they invest — bets that have a big impact on the payouts for the venture capital firm and any of its investors. \u003cbr\u003e\u003c\/p\u003e\n\u003cp data-renderer-start-pos=\"703\"\u003e\u003cspan style=\"font-family: -apple-system, BlinkMacSystemFont, 'San Francisco', 'Segoe UI', Roboto, 'Helvetica Neue', sans-serif; font-size: 1.4em;\"\u003eReview the 2021 edition of this report \u003c\/span\u003e\u003ca style=\"font-family: -apple-system, BlinkMacSystemFont, 'San Francisco', 'Segoe UI', Roboto, 'Helvetica Neue', sans-serif; font-size: 1.4em;\" href=\"https:\/\/reports.statnews.com\/products\/2021-ranking-biotechs-top-venture-capital-firms\"\u003ehere\u003c\/a\u003e\u003cspan style=\"font-family: -apple-system, BlinkMacSystemFont, 'San Francisco', 'Segoe UI', Roboto, 'Helvetica Neue', sans-serif; font-size: 1.4em;\"\u003e.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\" data-mce-style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this jaw-dropping report.\u003c\/p\u003e\n\u003cp\u003e\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/22140353-stat-report-18-venturecapital_preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" title=\"STAT 2022 Venture Capital report preview (Hosted by DocumentCloud)\" width=\"700\" height=\"905\" style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e\u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":39845538267239,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":39845538300007,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/VCFirms-Aug2022-MetaImage.png?v=1694195209"},{"product_id":"stat-guide-blockchain-in-health-care","title":"Health care’s big bet on blockchain","description":"\u003cp\u003e\u003cem\u003ePublished: Sept. 2022\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003eIt’s not just Bitcoin. In the fiercely competitive world of health care, blockchain technology is quickly becoming the next frontier, offering hospitals, insurance companies, health tech startups and others in the industry the potential to, among other things, increase the protection of patient data, cut costs and create a stronger bulwark against fraud. \u003cbr\u003e \u003cbr\u003eBut unless you’re a cryptocurrency aficionado, diving into the blockchain world and understanding the opportunities it opens up for the health care sector can be daunting.\u003cbr\u003e \u003cbr\u003eThis report is designed to give you a crash course, walking you through the technology’s concepts, terminology and health care applications, as well as the challenges that stand in its way. To put the report together, STAT spoke with dozens of executives across the health care sector, and took an in-depth look at the start-ups and established companies that are finding ways to use blockchain to increase the efficiency, profitability and security of patient care. \u003cbr\u003e \u003cbr\u003eThink of this report as your guide to health care’s big blockchain bet.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cspan\u003eHow it works\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eAdd this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-weight: 400;\" data-mce-style=\"font-weight: 400;\"\u003e\u003cspan\u003ePreview\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eTake a peek at what's included in this report.\u003c\/p\u003e\n\u003cp\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/22670354-stat-report-19-blockchain-v3_09-21-22-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" title=\"STAT-Report-19-Blockchain-v3_09-21-22 preview (Hosted by DocumentCloud)\" width=\"700\" height=\"905\" style=\"border: 1px solid #aaa; width: 100%; height: 800px; height: calc(100vh - 100px);\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e\u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":39882606411879,"sku":null,"price":299.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":39882606444647,"sku":null,"price":1495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Sep2022-MetaImage.png?v=1702404233"},{"product_id":"future-of-mrna","title":"The future of messenger RNA: Covid vaccines were just the beginning","description":"\u003cp\u003e\u003cem\u003ePublished: Nov. 2022\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eMessenger RNA, the same genetic material that pharmaceutical companies quickly harnessed to develop game-changing Covid-19 vaccines, is opening up a world of possibilities, and arming doctors with new tools to prevent or combat disease.\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn this report, STAT, the most authoritative source for reporting on innovations in health care and biotech, delves into the potential of mRNA. In it, you will:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFind out which 10 companies are at the forefront of mRNA research.\u003c\/li\u003e\n\u003cli\u003eHave enough background to understand just how transformative mRNA is likely to be.\u003c\/li\u003e\n\u003cli\u003eAnd get a sense of how mRNA is powering the next generation of gene-editing technologies, opening the door to new drugs and novel cancer treatments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/23307206-stat-report-20-future-of-mrna-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" title=\"STAT-Report-20-Future-of-mRNA preview (Hosted by DocumentCloud)\" width=\"700\" height=\"905\" style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":39951832154215,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":39951832186983,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Nov2022-MetaImage.png?v=1702404119"},{"product_id":"new-frontier-immunotherapy-precision-oncology","title":"Targeting cancer: the new frontier of immunotherapy and precision oncology","description":"\u003cp\u003e\u003cem\u003ePublished: Jan. 2023\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eNew technologies for fighting cancer are extending some patients’ lives and hold the vast potential to do the same for many others — in some cases offering cures for diseases that were once considered a death sentence. Immunotherapies rely on biological targets that scientists can use to turn the immune system into a weapon that kills cancer cells or disables the malignant cells’ defenses.\u003c\/p\u003e\n\u003cp\u003eThis report is an authoritative guide to these game-changing treatments, informed by STAT’s original reporting and expert analysis. In it, you will:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGet the latest information about these novel therapies and their successes and failures.\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003eGain an understanding of the biology of cancer targets and the strategies scientists are using in designing drugs to harness them.\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003eAnd learn about five cancer targets — LAG-3, TGF-beta, CLDN6, mesothelin, and KRAS — that pharmaceutical and biotech companies are actively pursuing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/23584148-stat-report-21-cancertargets-0120-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" title=\"STAT-Report-21-CancerTargets-120 preview (Hosted by DocumentCloud)\" width=\"700\" height=\"905\" style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":40001524924519,"sku":null,"price":149.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":40001524957287,"sku":null,"price":745.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/Jan2023-MetaImage.png?v=1702404044"},{"product_id":"treating-depression-report","title":"Treating Depression: A new era of promising drugs","description":"\u003cp data-renderer-start-pos=\"234\"\u003eA new generation of drugs for depression is stirring excitement and transforming the way scientists and clinicians diagnose, treat, and think about the illness. In a field that for decades has seen little significant innovation, these novel drugs — more than 60 are in the pipeline — raise the prospect of pharmaceutical treatments that are more precise, more individualized and more effective than any of their predecessors. And companies are racing to develop compounds that can dominate the market, as Prozac and Zoloft did in the 1990s. \u003c\/p\u003e\n\u003cp data-renderer-start-pos=\"777\"\u003eThis report, by Benedict Carey, a freelance science writer and the former human behavior reporter for The New York Times, offers you an authoritative look at the players and their prospects. In it, you will\u003c\/p\u003e\n\u003cul data-indent-level=\"1\" class=\"ak-ul\"\u003e\n\u003cli\u003e\n\u003cp data-renderer-start-pos=\"987\"\u003eLearn about the five families of compounds under development and the possibilities and pitfalls for companies hoping to bring them to market\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-renderer-start-pos=\"1131\"\u003eGain an understanding of the role psychedelics have played in pioneering this new frontier\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-renderer-start-pos=\"1225\"\u003eHear how neuroscientists and psychiatrists are changing their thinking about the diagnosis of depression and the best approach to treating patients\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/23726457-stat-report-22-treating-depression-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" title=\"STAT-Report-22-Treating Depression-preview (Hosted by DocumentCloud)\" width=\"700\" height=\"905\" style=\"border: 1px solid #aaa; width: 100%; height: 800px; height: calc(100vh - 100px);\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e\n\n\n\n\n\u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":40056062836839,"sku":null,"price":399.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":40056062869607,"sku":null,"price":1995.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/TreatingDepression-MetaImage.png?v=1702403829"},{"product_id":"clinical-trial-delays","title":"Clinical trial delays: what they mean and why you should care","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003cp data-renderer-start-pos=\"107\"\u003eWhen it comes to clinical trials, time is money. And a delay in a trial can mean a drop in a drug’s net value, lost ground to competitors, or an increased risk of failure — or it can signal more bad news to come.\u003c\/p\u003e\n\u003cp data-renderer-start-pos=\"321\"\u003eBut not all trial delays are red flags. How often is a pushed-back timeline a bad omen? How often is it a minor inconvenience? And how can you predict the difference? It’s not as easy as it sounds: It can be hard to get full information about trial delays, and details are often even sparser if the sponsor is a large pharma company or a private biotech.\u003c\/p\u003e\n\u003cp data-renderer-start-pos=\"677\"\u003eIn this special STAT Report, the first of three on clinical trials, biopharma consultant Frank David, M.D., Ph.D., author of two highly popular drug industry handbooks — “The Pharmagellan Guide to Analyzing Biotech Clinical Trials” and “The Pharmagellan Guide to Biotech Forecasting and Valuation” — provides the answers that people who track the progress of clinical trials need most. \u003c\/p\u003e\n\u003cp data-renderer-start-pos=\"1358\"\u003eIn this 28 page report, you will find:\u003c\/p\u003e\n\u003cul data-indent-level=\"1\" class=\"ak-ul\"\u003e\n\u003cli\u003e\n\u003cp data-renderer-start-pos=\"1400\"\u003eInformation about the various causes of trial delays, their potential impacts, and how to tell if you should be worried or not.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-renderer-start-pos=\"1531\"\u003eInsights from real-life examples of companies whose trials were pushed back.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-renderer-start-pos=\"1611\"\u003eProprietary analyses of the frequency, length, and impact of holdups in a clinical trial’s timeline.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cem\u003eInterested in more reports on clinical trials?\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eGain special access to Frank David’s clinical trial series for a fraction of the cost. This bundle deal gives you a discount on all three reports focused on clinical trials.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eAdd the below reports to your cart and use the discount code \u003cstrong\u003eBUNDLE\u003c\/strong\u003e at checkout to save $150.\u003c\/em\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel=\"noopener\" href=\"https:\/\/reports.statnews.com\/collections\/reports-part-3-20-29\/products\/clinical-trial-delays\" target=\"_blank\"\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eClinical trial delays: What they mean and why you should care \u003c\/span\u003e\u003c\/em\u003e\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca rel=\"noopener\" href=\"https:\/\/reports.statnews.com\/collections\/reports-part-3-20-29\/products\/failed-trial-successful-drug\" target=\"_blank\"\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eFailed trial, successful drug: How a negative readout can lead to FDA approval\u003c\/span\u003e\u003c\/em\u003e\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca rel=\"noopener\" href=\"https:\/\/reports.statnews.com\/collections\/30-39-reports-collection\/products\/subgroup-analysis-clinical-trials\" target=\"_blank\"\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eClinical trial subgroup analysis: How to evaluate post hoc tests for significance in clinical trials\u003c\/span\u003e\u003c\/em\u003e\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":40079994486887,"sku":"","price":149.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":40079994519655,"sku":"","price":745.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/products\/MetaImage-ClinicalTrialDelays.png?v=1681658127"},{"product_id":"will-medicare-pay-for-it","title":"Decoding Medicare: 10 key decisions and how they're made","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003cp data-renderer-start-pos=\"107\"\u003e\u003cstrong\u003eWill Medicare pay?\u003c\/strong\u003e The answer to that question often means success or failure for novel drugs and devices, influences the choices made by private insurance plans, and affects the adoption of emerging technologies like gene and cell therapies and artificial intelligence.\u003cbr\u003e\u003c\/p\u003e\n\u003cp data-renderer-start-pos=\"107\"\u003eBut Medicare’s decisions about coverage usually come wrapped in all-but-impenetrable directives and policy statements, accompanied by a slew of acronyms. \u003cbr\u003e\u003c\/p\u003e\n\u003cp data-renderer-start-pos=\"107\"\u003e\u003cstrong\u003eThis report was designed to guide you through the Medicare maze\u003c\/strong\u003e, deciphering its insider terminology and showing you how the massive federal program decides what to cover and which entities lie behind those determinations.\u003cbr\u003e\u003c\/p\u003e\n\u003cp data-renderer-start-pos=\"107\"\u003eWritten by Kerry Dooley Young, a reporter who has covered Medicare for almost two decades, it is an essential resource for anyone involved or simply interested in health care or health policy — especially at a time when Medicare is demanding more evidence for the safety and effectiveness of new products, even those already approved by the Food and Drug Administration. \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eThis report is for:\u003c\/strong\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiotech and pharmaceutical company leaders\u003c\/strong\u003e, whose drug or device development often hinges on obtaining Medicare coverage\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHospitals executives, physicians and other medical professionals\u003c\/strong\u003e, whose reimbursement for novel treatments may be affected by Medicare’s coverage decisions\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatients with Medicare or Medicare Advantage plans\u003c\/strong\u003e hoping to obtain coverage for new drugs and devices\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAnyone interested in health care and health care policy\u003c\/strong\u003e who wants to understand how Medicare operates and how the federal program will handle today’s rapid advances in medical technology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-renderer-start-pos=\"107\"\u003e\u003cstrong\u003eIn this report, you will find:\u003c\/strong\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eA breakdown of 10 important decisions Medicare has made or is in the process of making, including recent ones on Biogen’s Alzheimer’s drug Aduhelm, CAR-T, and popular weight loss drugs.\u003c\/li\u003e\n\u003cli\u003eAn explanation of what Medicare’s new demand for more evidence means for drug and device makers.\u003c\/li\u003e\n\u003cli\u003eA glossary of the acronyms that make up Medicare-speak.\u003c\/li\u003e\n\u003cli\u003eAn analysis of how Medicare defines “necessary and reasonable.”\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ciframe style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" height=\"905\" width=\"700\" title=\"STAT-Report-23-Decoding Medicare - Preview (Hosted by DocumentCloud)\" src=\"https:\/\/embed.documentcloud.org\/documents\/23824041-stat-report-23-decoding-medicare-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":40111133884519,"sku":null,"price":399.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":40111133917287,"sku":null,"price":1995.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/MetaImage-DecodingMedicare.png?v=1684522574"},{"product_id":"2023-ranking-biotechs-top-venture-capital-firms","title":"2023 Update: Ranking Biotech’s Top Venture Capital Firms","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eThis report — the fourth in as many years — digs deep to show how much has changed since last year’s financial successes of the Covid-19 biopharma industry boom.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cstrong\u003eLooking at which venture capital firms have made the best investments\u003c\/strong\u003e and their payouts for investors, Kate Sheridan and STAT’s Allison DeAngelis break down the numbers for more than a dozen of the biggest names in biotech venture capital: Atla Partners, Flagship Pioneering, OrbiMed, Third Rock Ventures, and Versant Ventures. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eIncluding new 2022 data, we have combed through dozens of private returns to provide you with a definitively ranked list. In this report,\u003cstrong\u003e learn which firms have been most successful\u003c\/strong\u003e in betting on the biotech companies they invest in, company’s strategy behind their performance, and insights on \u003cstrong\u003ewho delivered the best returns to their investors\u003c\/strong\u003e, all in our 2023 Update: Ranking Biotech’s Top Venture Capital Firms.\u003c\/span\u003e \u003c\/p\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/23879127-stat-report-ranking-bio-techs-top-vc-firms-2023-edition-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" title=\"STAT Report - Ranking Bio Tech's Top VC Firms 2023 Edition preview (Hosted by DocumentCloud)\" width=\"700\" height=\"905\" style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":40163237003367,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":40163237036135,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/MetaImage-VCFirms.png?v=1689689113"},{"product_id":"patientsspeakout","title":"Patients speak out: Learning from patient stories to transform health care","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eThe health care world can be a noisy place: people shouting about regulation or chattering about costs and profits; scientists quibbling about clinical trial results; hospital alarms going off; the wailing of emergency sirens. With all the din, the patient’s voice often gets lost.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eIn this STAT special report, those lost voices speak out, in a collection of moving and deeply human first-person essays \u003c\/b\u003e\u003cspan style=\"font-weight: 400;\"\u003eoriginally published in our First Opinion column. The authors write about their experiences as patients, but also as parents, as people who themselves work in the health care system, \u003c\/span\u003eas\u003cspan style=\"font-weight: 400;\"\u003e volunteers who participate in clinical trials.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eThey write of feeling unheard or unseen. They share their vulnerabilities and their pain. They raise concerns but also describe what helped them, and made them stronger.Together, the pieces are a reminder of the humanity at the core of what health care is about, \u003c\/span\u003e\u003cb\u003eoffering lessons that can help regulators, health care professionals, and drug developers\u003c\/b\u003e\u003cspan style=\"font-weight: 400;\"\u003e improve outcomes for future patients.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eDownload this report, and hear what they have to say. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ciframe style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" height=\"905\" width=\"700\" title=\"STATSpecialReport_Patientsspeakout preview (Hosted by DocumentCloud)\" src=\"https:\/\/embed.documentcloud.org\/documents\/23885831-statspecialreport_patientsspeakout-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":40169397059687,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":40169397092455,"sku":null,"price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/MetaImage-PatientVoices.png?v=1690236897"},{"product_id":"failed-trial-successful-drug","title":"Failed trial, successful drug: How a negative readout can lead to FDA approval","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eA failed late-stage clinical trial is bad news for patients, the drugmaker, and investors who made a bet that the product would be successful. But it doesn’t always mean the end of the road for a new drug.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eIn our latest report, \u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003ebiopharma consultant Frank David, M.D., Ph.D., author of two highly popular drug industry handbooks — “The Pharmagellan Guide to Analyzing Biotech Clinical Trials” and “The Pharmagellan Guide to Biotech Forecasting and Valuation” \u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003e \u003cstrong\u003eexplores the regulatory rules that give the FDA the flexibility to approve a drug and aims to help investors and biotech companies evaluate negative clinical studies\u003c\/strong\u003e to assess whether there's still a viable path to market. It also covers what may be the most critical factor in getting therapies with negative data approved — the sponsor’s relationship and experience with the agency.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eWhile drug approval is expected to be based on safety and effectiveness, several drugs have been approved by the FDA despite mixed or negative clinical results, while others were rejected. In this report, we’ll show how early signs in a drug’s developmental path can predict trouble and why.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eClinical trial failures are a part of life in biotech, but they don’t have to mean the end of the road for promising new therapies.\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eInterested in more reports on clinical trials? \u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eGain special access to Frank David’s clinical trial series for a fraction of the cost. This bundle deal gives you a discount on all three reports focused on clinical trials. \u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eAdd the below reports to your cart and use the discount code \u003cstrong\u003eBUNDLE\u003c\/strong\u003e at checkout to save $150.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/reports.statnews.com\/collections\/reports-part-3-20-29\/products\/clinical-trial-delays\" target=\"_blank\" rel=\"noopener\"\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eClinical trial delays: What they mean and why you should care \u003c\/span\u003e\u003c\/em\u003e\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/reports.statnews.com\/collections\/reports-part-3-20-29\/products\/failed-trial-successful-drug\" target=\"_blank\" rel=\"noopener\"\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eFailed trial, successful drug: How a negative readout can lead to FDA approval\u003c\/span\u003e\u003c\/em\u003e\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/reports.statnews.com\/collections\/30-39-reports-collection\/products\/subgroup-analysis-clinical-trials\" target=\"_blank\" rel=\"noopener\"\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eClinical trial subgroup analysis: How to evaluate post hoc tests for significance in clinical trials\u003c\/span\u003e\u003c\/em\u003e\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ciframe style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" height=\"905\" width=\"700\" title=\"STAT Report - Failed trial, successful drug 2023 preview (Hosted by DocumentCloud)\" src=\"https:\/\/embed.documentcloud.org\/documents\/23901852-stat-report-failed-trial-successful-drug-2023-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":40178917245031,"sku":null,"price":149.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":40178917277799,"sku":null,"price":745.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/MetaImage-ClinicalTrialsReport2-Retina.png?v=1691444311"},{"product_id":"climate-rankings","title":"Climate Rankings: How top drug companies measure up in combating climate change","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003cp\u003e\u003cspan style=\"font-family: -apple-system, BlinkMacSystemFont, 'San Francisco', 'Segoe UI', Roboto, 'Helvetica Neue', sans-serif; font-size: 0.875rem;\"\u003e\u003cmeta charset=\"utf-8\"\u003e \u003cb data-mce-fragment=\"1\"\u003eThis exclusive report is the first comprehensive guide to how biotech and pharma companies are combating climate change\u003c\/b\u003e\u003cspan data-mce-fragment=\"1\"\u003e, ranking them on their efforts to understand and reduce their greenhouse gas emissions. Based on data compiled from a variety of public sources, STAT conducted an exclusive analysis, \u003c\/span\u003e\u003cb data-mce-fragment=\"1\"\u003eusing 20 different metrics to rate companies on transparency, credibility, scope, and implementation of climate policies.\u003c\/b\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-family: -apple-system, BlinkMacSystemFont, 'San Francisco', 'Segoe UI', Roboto, 'Helvetica Neue', sans-serif; font-size: 0.875rem;\"\u003ePharmaceutical and biotech companies are major contributors to climate change, through direct emissions and also through their supply and value chains. But the drug industry has trailed far behind in tracking its carbon footprint, much less trying to reduce it.\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eThat’s changing as companies are coming under increasing pressure to take action on climate change from investors and other stakeholders, including government regulators, customers, and their own employees.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eThere’s been no easy way, however, to find out what individual companies are doing — if they’re doing anything at all.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eUntil now.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eIn the report, you will:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eGain an understanding of the pharma and biotech industries’ contribution to climate change and what the challenges are to measuring and reporting emissions. \u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eExplore how more than 30 companies are ranked, along with detailed data about their climate efforts and how we evaluated them, and why a majority of the 100 top companies are not doing anything at all.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cul\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eLearn what steps some companies are taking to address global warming, who is directing those efforts, and how companies that want to take action can begin doing so.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eAdditionally, a free spreadsheet with the full data for all 33 companies will accompany this report as an added bonus.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ciframe style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" height=\"905\" width=\"700\" title=\"STAT Report - Climate Rankings 2023 Preview (Hosted by DocumentCloud)\" src=\"https:\/\/embed.documentcloud.org\/documents\/23993034-stat-report-climate-rankings-2023-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":40219209400423,"sku":null,"price":199.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":40219209433191,"sku":null,"price":995.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/MetaImage-ClimateReport.png?v=1695823806"},{"product_id":"subgroup-analysis-clinical-trials","title":"Clinical trial subgroup analysis: How to evaluate post hoc tests for significance in failed clinical trials","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003cp\u003eIf you spend enough time following biotech, you’ll encounter a common situation: A big clinical trial fails, but the company points to a glimmer of an effect in a subset of patients. The next thing you know, the firm is launching a big follow-up study focused on that subgroup, often accompanied by a big fundraising push. There are good reasons to be skeptical of these follow up studies, but they can yield important insights that are ultimately green-lighted by regulators.\u003cbr\u003e\u003cbr\u003eIn this report, biopharma consultant Frank David, M.D., Ph.D., author of two highly popular drug industry handbooks — “The Pharmagellan Guide to Analyzing Biotech Clinical Trials” and “The Pharmagellan Guide to Biotech Forecasting and Valuation,” \u003cstrong\u003ehelps to evaluate these subgroup analyses as either a source of hope or a red herring.\u003c\/strong\u003e \u003cbr\u003e\u003cbr\u003eIt's crucial to neither be overly optimistic nor dismissive of post hoc subgroup analyses. Instead, our report emphasizes the significance of focusing on the data. \u003cstrong\u003eThis report is designed to help investors, researchers, patients, and others interested in the success or failure of an experimental drug navigate this uncertain terrain with clarity and data-driven insights\u003c\/strong\u003e. By doing so, you can make a clear-eyed assessment of the likelihood that a trial replicating post hoc findings will yield positive results.\u003cbr\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eInterested in more reports on clinical trials?\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eGain special access to Frank David’s clinical trial series for a fraction of the cost. This bundle deal gives you a discount on all three reports focused on clinical trials.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eAdd the below reports to your cart and use the discount code \u003cstrong\u003eBUNDLE\u003c\/strong\u003e at checkout to save $150.\u003c\/em\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel=\"noopener\" href=\"https:\/\/reports.statnews.com\/collections\/reports-part-3-20-29\/products\/clinical-trial-delays\" target=\"_blank\"\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eClinical trial delays: What they mean and why you should care \u003c\/span\u003e\u003c\/em\u003e\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca rel=\"noopener\" href=\"https:\/\/reports.statnews.com\/collections\/reports-part-3-20-29\/products\/failed-trial-successful-drug\" target=\"_blank\"\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eFailed trial, successful drug: How a negative readout can lead to FDA approval\u003c\/span\u003e\u003c\/em\u003e\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca rel=\"noopener\" href=\"https:\/\/reports.statnews.com\/collections\/30-39-reports-collection\/products\/subgroup-analysis-clinical-trials\" target=\"_blank\"\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003eClinical trial subgroup analysis: How to evaluate post hoc tests for significance in clinical trials\u003c\/span\u003e\u003c\/em\u003e\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ciframe style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" height=\"905\" width=\"700\" title=\"STAT Report Subgroup Analysis preview (Hosted by DocumentCloud)\" src=\"https:\/\/embed.documentcloud.org\/documents\/24101276-stat-report-subgroup-analysis-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":40263505707111,"sku":null,"price":149.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":40263505739879,"sku":null,"price":745.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/MetaImage-FrankReport3.png?v=1698770960"},{"product_id":"stat-guide-interpreting-clinical-trials-update","title":"2023 Update: STAT’s guide to interpreting clinical trial results","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eInterpreting clinical trial results is not for the faint of heart. \u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003eThis report addresses the critical issue of spin in clinical trials. It emphasizes the need for vigilance when evaluating such trials' results, as misleading information can be concealed beneath apparently positive findings. But there is an art to reading and writing\u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003e scientific findings — and you can learn it.\u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003eIn this update of STAT’s bestselling report, \u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003e\u003cstrong\u003ethe authors provide tools to approach clinical trial results with skepticism and critical thinking, aiming to empower readers to discern reliable research from potentially biased or misleading information\u003c\/strong\u003e. The report will further explore potential red flags, illustrating challenges faced during clinical trials, from their inception and execution to their final reporting.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eThis report seeks to educate readers about the pitfalls and potential biases within clinical trial reporting, enabling them to make more informed judgments about the efficacy of various treatments and interventions to make smarter business decisions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eIn this report, you will find:\u003c\/b\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eA definition of spin in clinical trials, supported by real life examples.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eFour key questions to ask when evaluating clinical trial results, and an overview of additional tools you need to read results more critically.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eAnalysis of the red flags you should look for in clinical trial design, execution, and reporting of results.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/24176115-2023-update-stats-guide-to-clinical-trial-nov-2023-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" title=\"2023 Update - STAT's guide to clinical trial Nov 2023 preview (Hosted by DocumentCloud)\" width=\"700\" height=\"905\" style=\"border: 1px solid #aaa; width: 100%; height: 800px; height: calc(100vh - 100px);\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e\n","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":40308516356199,"sku":null,"price":49.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":40308516388967,"sku":null,"price":245.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/MetaImage-Nov23Report.png?v=1701119396"},{"product_id":"the-obesity-revolution-how-glp-1-drugs-are-changing-society","title":"The Obesity Revolution: How GLP-1 drugs are changing science, business, health care, and society","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003cp\u003eNew GLP-1-based obesity drugs like Ozempic and Wegovy are reshaping health care and society. The Obesity Revolution is an in-depth exploration of how these GLP-1 drugs are reshaping science, business, health care, and society. \u003cstrong\u003eDiscover how these groundbreaking treatments are making waves in medical circles and beyond\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eDive into the rapidly evolving landscape of obesity medications, where pharma giants like Novo Nordisk and Eli Lilly vie for dominance in a market projected to reach $100 billion. Uncover the challenges faced by payers amidst the soaring costs of lifelong treatment.\u003c\/p\u003e\n\u003cp\u003eExplore the surprising science behind these drugs, originally developed for diabetes but now showing promise in curbing food cravings and addictive behaviors. Gain insights into their potential to redefine how doctors approach medicine and challenge societal perceptions of disease.\u003c\/p\u003e\n\u003cp\u003eWith debates on obesity definitions and medicalization heating up, this report navigates the complexities of a revolution just beginning. Embrace the era of Ozempic and beyond – \u003cstrong\u003ethe obesity revolution is here\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ciframe style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" height=\"905\" width=\"700\" title=\"STAT Report The Obesity Revolution preview (Hosted by DocumentCloud)\" src=\"https:\/\/embed.documentcloud.org\/documents\/24493567-stat-report-the-obesity-revolution-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":40497160257639,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":40497160290407,"sku":null,"price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/ObesityRevolutionReport_MetaImage_1.png?v=1711042949"},{"product_id":"biotech-top-venture-capital-firms-2024","title":"2024 Edition: Ranking Biotech’s Top Venture Capital Firms","description":"\u003ch2\u003eWhich venture capital firms are delivering the best returns in the dynamic biotech industry?\u003c\/h2\u003e\n\u003cp\u003eThis STAT Report, now in its fifth year, offers an exclusive, data-driven analysis of the top-performing venture capital firms.\u003c\/p\u003e\n\u003cp\u003eIn this comprehensive report, STAT News’ \u003ca href=\"https:\/\/www.statnews.com\/staff\/allison-deangelis\"\u003eAllison DeAngelis\u003c\/a\u003e dives into the financial performance and strategic decisions of over a dozen leading biotech venture capital firms, including new names joining this year’s list.\u003c\/p\u003e\n\u003cp\u003eWith a wealth of new data from 2023, uncover the latest trends and moves in biotech investment. Whether you’re an investor, industry professional, or simply interested in the financial dynamics of biotech, this 2024 STAT Report ranking VC companies is \u003cstrong\u003eyour essential guide to understanding the forces driving success\u003c\/strong\u003e in this high-stakes sector.\u003c\/p\u003e\n\u003ch3\u003eWhat’s Inside the STAT Report?\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eA detailed ranking of biotech venture capital firms based on their returns\u003c\/li\u003e\n\u003cli\u003eExclusive analysis by STAT News’ Allison DeAngelis on the financial strategies and successes of top firms\u003c\/li\u003e\n\u003cli\u003eKey trends and new entrants in the biotech investment landscape\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eFor information on licensing this report for external distribution or marketing, please \u003ca href=\"https:\/\/www.parsintl.com\/publications\/stat\/\" rel=\"noopener\" target=\"_blank\"\u003evisit our partners at PARS here\u003c\/a\u003e. Please also refer to the \u003ca href=\"https:\/\/reports.statnews.com\/pages\/terms-and-conditions\"\u003eTerms and Conditions\u003c\/a\u003e for additional information on use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/25032822-stat-news-report-ranking-biotechs-top-vc-firms-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" title=\"STAT News Report - Ranking Biotechs Top VC Firms preview (Hosted by DocumentCloud)\" width=\"700\" height=\"905\" style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eReview the \u003ca href=\"https:\/\/reports.statnews.com\/collections\/all-reports\/products\/2023-ranking-biotechs-top-venture-capital-firms\"\u003e2023 edition of this report here\u003c\/a\u003e.\u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":40943716958311,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":40943716991079,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/STAT_News_Report_Ranking_Top_VC_Firms_MetaImage.png?v=1722890140"},{"product_id":"h5n1-bird-flu","title":"Understanding H5N1 bird flu: Research, risks, and prevention","description":"\u003ch2\u003eHow does H5N1 bird flu behave in cows and beyond?\u003c\/h2\u003e\n\u003cp\u003eH5N1 bird flu has taken an unexpected turn—one that has caught the attention of scientists and dairy farmers alike. Known for wreaking havoc in poultry flocks, \u003cstrong\u003ethis highly pathogenic virus has now been found in dairy cows\u003c\/strong\u003e in the U.S., sparking concerns about its potential to spread among mammals. Could this virus, which has been monitored for decades for its pandemic potential, evolve to become a greater threat?\u003c\/p\u003e\n\u003cp\u003eOur comprehensive report compiles essential coverage from STAT, highlighting the new risks posed by H5N1’s move into dairy herds. It dives into how this virus, traditionally lethal in poultry, is causing subtle but significant changes in cows. Infected cows don't show the same dramatic symptoms as poultry, but the risk of widespread undetected transmission is growing.\u003c\/p\u003e\n\u003cp\u003eDon’t miss out on the chance to \u003cstrong\u003euncover why scientists warn of the possibility of adaptation leading to the spread in other mammals\u003c\/strong\u003e, which could lead to a pandemic.\u003c\/p\u003e\n\u003ch3\u003eKey insights include:\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eRecent cases of H5N1 in dairy cows in the U.S.\u003c\/li\u003e\n\u003cli\u003eThe virus's unexpected ability to persist in cows and risks\u003c\/li\u003e\n\u003cli\u003eChallenges faced by dairy farmers and veterinarians\u003c\/li\u003e\n\u003cli\u003eThe global scientific response\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eStay informed on H5N1’s evolving threat, the science behind its behavior in cows, and the global implications if this virus continues to spread. \u003cstrong\u003eDownload this report to learn how experts are responding\u003c\/strong\u003e—and what’s at stake for both agriculture and public health.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003ciframe style=\"border: 1px solid #aaa; width: 100%; height: calc(100vh - 100px);\" height=\"905\" width=\"700\" title=\"STAT_Report_H5N1_Bird_Flu_preview (Hosted by DocumentCloud)\" src=\"https:\/\/embed.documentcloud.org\/documents\/25197598-stat_report_h5n1_bird_flu_preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e\u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":41042090983527,"sku":null,"price":19.99,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":41042091016295,"sku":null,"price":99.95,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/BirdFluReport_Wordpress_MetaImage.png?v=1728507853"},{"product_id":"medicare-advantage-explained","title":"Medicare Advantage decoded: Care, coverage, and a changing health care system","description":"\u003ch2\u003e\u003cb id=\"docs-internal-guid-0df34248-7fff-5e5e-50ab-d62fcb4a49a8\"\u003e\u003cspan\u003eExplore what Medicare Advantage means\u003c\/span\u003e\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eMore than half of all Medicare beneficiaries are now insured through private Medicare Advantage plans, and this massively profitable niche of health insurance raises questions about how taxpayer money is being spent. There has never been a more important time to understand the ins and outs of this growing program than right now.\u003c\/p\u003e\n\u003cp\u003eThis collection of articles from STAT’s Medicare Advantage coverage includes new analyses and charts based on the latest data from the federal government.\u003c\/p\u003e\n\u003ch3\u003eGain a better understand of:\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli style=\"font-style: italic;\"\u003e\u003cem\u003eHow Medicare Advantage works\u003c\/em\u003e\u003c\/li\u003e\n\u003cli style=\"font-style: italic;\"\u003e\u003cem\u003eHow it compares to traditional Medicare\u003c\/em\u003e\u003c\/li\u003e\n\u003cli style=\"font-style: italic;\"\u003e\u003cem\u003eTop health insurance companies dominating the industry\u003c\/em\u003e\u003c\/li\u003e\n\u003cli style=\"font-style: italic;\"\u003e\u003cem\u003eWhat is changing heading into 2025\u003c\/em\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePerhaps the most important and controversial component of Medicare Advantage is “risk adjustment” — the process by which the government pays insurance companies for each individual based on how sick that person is. In this system, private insurers receive federal subsidies to manage care, with the \u003cstrong\u003egovernment spending over $500 billion annually on the program\u003c\/strong\u003e. However, shifting America’s Medicare program toward a more privatized version has not saved taxpayers any money and has restricted care for vulnerable patients.\u003c\/p\u003e\n\u003cp\u003eExplore which companies, in addition to AT\u0026amp;T and Boeing, have shifted their retirees to Medicare Advantage included in the over \u003cstrong\u003e34 million enrollees in 2024\u003c\/strong\u003e. While the program’s benefits are appealing, concerns persist about its impact on costs and care quality. Given these plans' growing influence, it's more important than ever to have a clear-eyed perspective on the repercussions for physicians, insurers, and patients. \u003c\/p\u003e\n\u003cp\u003eDownload this report to \u003cstrong\u003egain a broader understanding of the state of Medicare Advantage\u003c\/strong\u003e and its implications.\u003c\/p\u003e\n\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/25418409-stat-report-medicare-advantage-decoded-preview\/?embed=1\u0026amp;responsive=1\u0026amp;title=1\" title=\"STAT Report - Medicare Advantage Decoded Preview (Hosted by DocumentCloud)\" width=\"700\" height=\"905\" style=\"border: 1px solid #aaa; width: 100%; height: 800px; height: calc(100vh - 100px);\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-forms allow-popups-to-escape-sandbox\"\u003e\u003c\/iframe\u003e\n","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":41095403929703,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":41095403962471,"sku":null,"price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/NovMedicareAdvantage_Wordpress_MetaImage.png?v=1732660623"},{"product_id":"ai-in-health-care-opportunities-and-risks","title":"AI in health care: Opportunities, risks, and the road ahead","description":"\u003ch2\u003e\u003cb id=\"docs-internal-guid-0df34248-7fff-5e5e-50ab-d62fcb4a49a8\"\u003e\u003cspan\u003eDiscover where AI innovation meets health care\u003c\/span\u003e\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eIn this comprehensive report, you can explore artificial intelligence's transformative role in medicine and how the technology carries far-reaching consequences for health, safety, privacy, and fairness.\u003c\/p\u003e\n\u003ch3\u003eUncover the promises and perils of AI\u003c\/h3\u003e\n\u003cp\u003eActing as an expertly crafted AI resource, STAT's report offers unparalleled insights into its rapid adoption across hospitals, insurers, and pharmaceutical companies. From generative AI breakthroughs to machine learning applications, explores how these technologies are reshaping \u003cstrong\u003ecare delivery, drug development, and administrative processes\u003c\/strong\u003e — often without fully understanding their impact on patients, providers, and society at large. In this report, you will: \u003c\/p\u003e\n\u003cul\u003e\n\u003cli style=\"font-style: italic;\"\u003e\u003cem\u003eGain a front-row seat to the regulatory debates shaping the future\u003c\/em\u003e\u003c\/li\u003e\n\u003cli style=\"font-style: italic;\"\u003e\u003cem\u003eMeet the thought leaders defining its narrative\u003c\/em\u003e\u003c\/li\u003e\n\u003cli style=\"font-style: italic;\"\u003e\u003cem\u003eExplore groundbreaking case studies (including \u003ca rel=\"noopener\" href=\"https:\/\/www.statnews.com\/denied-by-ai-unitedhealth-investigative-series\/\" target=\"_blank\"\u003eSTAT’s Pulitzer-nominated investigation\u003c\/a\u003e into algorithm-driven coverage decisions) \u003c\/em\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eDownload the report today to join the conversation about the road ahead for AI in health care — and how we can ensure its advances \u003cstrong\u003eserve patients, not just profits\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ciframe src=\"https:\/\/www.statnews.com\/wp-content\/uploads\/2025\/01\/STATNews_AIinHealthCare_Report_Preview.pdf#toolbar=0\" width=\"100%\" height=\"600px\" style=\"border: 1px solid #d8dee2; border-radius: 0.5rem;\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":41148515221607,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":41148515254375,"sku":null,"price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/DecAIMedicine_Wordpress_MetaImage.png?v=1736287820"},{"product_id":"inside-the-unitedhealth-group-empire","title":"From insurer to industry titan: Inside UnitedHealth’s empire","description":"\u003ch2\u003e\u003cb id=\"docs-internal-guid-0df34248-7fff-5e5e-50ab-d62fcb4a49a8\"\u003e\u003cspan\u003eExplore the power, profits, and pressures of the health care giant\u003c\/span\u003e\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eDiscover how UnitedHealth Group quietly grew from a traditional health insurer into one of the most powerful — \u003cem\u003eand controversial\u003c\/em\u003e — players in American health care.\u003c\/p\u003e\n\u003ch3\u003eInside the business of modern health care\u003c\/h3\u003e\n\u003cp\u003eIn STAT’s award-winning investigative series \u003ca rel=\"noopener\" href=\"https:\/\/www.statnews.com\/unitedhealth-group-investigation-health-care-colossus-series\/\" target=\"_blank\"\u003eHealth Care’s Colossus\u003c\/a\u003e, we uncover how the $400 billion company acquired physician groups, surgery centers and pharmacies while keeping its name hidden behind local brands. Today, UnitedHealth employs or affiliates with nearly 90,000 doctors — more than 10% of U.S. physicians — and is the nation’s third-largest company by revenue in 2024.\u003cem\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eLearn how UnitedHealth strategically profits by funneling patients into its own networks, paying itself more than competitors and pressuring doctors to maximize Medicare Advantage billing — often at the expense of clinical judgment. \u003cmeta charset=\"utf-8\"\u003eSTAT’s in-depth reporting exposes how this vast empire affects patient care, doctor autonomy and health care costs.\u003c\/p\u003e\n\u003cp\u003eAs bipartisan calls grow to break up the company and federal investigations intensify, the stakes have never been higher. Whether through \u003cstrong\u003einsurance, medical care or a major data breach\u003c\/strong\u003e, UnitedHealth likely touches your life or that of someone you love. With nearly every American affected in some way, understanding their influence is essential.\u003c\/p\u003e\n\u003cp\u003eA company this consequential must be examined and understood — even if it doesn’t want to be. At STAT, we won’t stop doing that. In this report, explore the power, profits and pressures behind America’s most dominant health care company — and the reckoning it now faces.\u003c\/p\u003e\n\u003cp\u003eRead the full report and uncover the truth about UnitedHealth’s rise to power.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003ciframe style=\"border: 1px solid #d8dee2; border-radius: 0.5rem;\" height=\"600px\" width=\"100%\" src=\"https:\/\/embed.documentcloud.org\/documents\/25924897-inside_unitedhealths_empire_statreport_preview\/?embed=1\"\u003e\u003c\/iframe\u003e\u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":41340165652583,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":41340165685351,"sku":null,"price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/UHCReport_Wordpress_MetaImage_1.png?v=1746121208"},{"product_id":"biotech-top-venture-capital-firms-2025","title":"2025 Edition: Ranking Biotech’s Top Venture Capital Firms","description":"\u003ch2\u003eYour ultimate guide to the closed-off world of biotech venture capital\u003c\/h2\u003e\n\u003cp\u003eNow in its sixth year, the STAT Report, \u003cem\u003eRanking Biotech’s Top Venture Capital Firms,\u003c\/em\u003e has become the go-to guide for understanding who’s truly delivering in the high-stakes world of biotech investing. Based on the latest performance data, this year’s edition offers our most comprehensive, data-driven analysis yet, including firm rankings, strategic insights, and new names making waves in the biotech VC space.\u003c\/p\u003e\n\u003cp\u003eFrom industry giants to emerging powerhouses, STAT News’ \u003ca href=\"https:\/\/www.statnews.com\/staff\/allison-deangelis\/\" rel=\"noopener\" target=\"_blank\"\u003eAllison DeAngelis\u003c\/a\u003e unpacks the stories behind the numbers.\u003c\/p\u003e\n\u003ch3\u003eInside the 2025 STAT Report, you’ll get:\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eRankings of top biotech VC firms based on private return data\u003c\/li\u003e\n\u003cli\u003eAnalysis of firm strategies, successes, and trends\u003c\/li\u003e\n\u003cli\u003eFresh data revealing how investors performed in a volatile market\u003c\/li\u003e\n\u003cli\u003eShifts among legacy players and newcomers to watch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eWhy This Report Matters\u003c\/h3\u003e\n\u003cp\u003eThe biotech venture capital space is evolving fast, and so are the firms driving it. STAT's unique methodology offers a sweeping examination of biotech VC operations, unlike any other. Whether you’re an investor, a startup founder looking for the right backers, or simply someone watching where \u003ca rel=\"noopener\" href=\"https:\/\/www.statnews.com\/2025\/01\/09\/obesity-startup-verdiva-bio\/\" target=\"_blank\"\u003esome of biotech’s money\u003c\/a\u003e is going, this report gives you a clear view of who’s delivering the best returns and why.\u003c\/p\u003e\n\u003cp\u003e\u003ciframe style=\"border: 1px solid #d8dee2; border-radius: 0.5rem; width: 100%; height: 100%; aspect-ratio: 8.5 \/ 11;\" height=\"11\" width=\"8.5\" src=\"https:\/\/embed.documentcloud.org\/documents\/26069951-ranking-vc-firms-report-2025-preview\/?embed=1\"\u003e\u003c\/iframe\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eAdd the \u003ca href=\"https:\/\/reports.statnews.com\/collections\/all-reports\/products\/biotech-top-venture-capital-firms-2024?\"\u003e2024 Edition\u003c\/a\u003e and 2025 Edition to your cart and save big! When purchasing both, you'll enjoy an 80% discount on the 2024 edition automatically applied in your cart at checkout.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eFor information on licensing this report for external distribution or marketing, please \u003ca href=\"https:\/\/www.parsintl.com\/publications\/stat\/\" rel=\"noopener\" target=\"_blank\"\u003evisit our partners at PARS here\u003c\/a\u003e. Please also refer to the \u003ca href=\"https:\/\/reports.statnews.com\/pages\/terms-and-conditions\"\u003eTerms and Conditions\u003c\/a\u003e for additional information on use.\u003c\/em\u003e\u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":41622773235815,"sku":null,"price":499.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":41622773268583,"sku":null,"price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/VCFirms2025_MetaImage.png?v=1780079763"},{"product_id":"inside-the-fda-under-trump","title":"Chaotic and politicized: Inside the FDA under Trump","description":"\u003ch2\u003e\u003cb id=\"docs-internal-guid-0df34248-7fff-5e5e-50ab-d62fcb4a49a8\"\u003e\u003cspan\u003eAn inside look at a regulator in turmoil\u003c\/span\u003e\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eThe FDA is supposed to be one of the most stable, science-driven agencies in the federal government. Over the past year, that foundation has been shaken. This STAT special report delivers a clear, authoritative look at how leadership turmoil and political pressure have transformed the agency and why it matters for patients, businesses, public health officials, and \u003cem\u003e\u003cstrong\u003eyou\u003c\/strong\u003e\u003c\/em\u003e.\u003c\/p\u003e\n\u003ch3\u003eWhy FDA instability matters for patients and industry\u003c\/h3\u003e\n\u003cp\u003eDrawing on months of in-depth reporting, STAT reveals how mass layoffs, rapid staff departures, and revolving-door leadership have destabilized the FDA under Commissioner Marty Makary. Once-private conflicts spilled into public view, top regulators were forced out or replaced, and long-standing norms meant to protect scientific independence began to shift. \u003cem\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eThese changes are already affecting real-world decisions: vaccine approvals overridden, surveillance systems reshaped, and agency scientists pushed to explore controversial theories. For drugmakers and biotech companies, the uncertainty has made FDA guidance harder to rely on. For the public, it raises urgent questions about trust.\u003c\/p\u003e\n\u003cp\u003eThis STAT Special Report brings clarity to a fast-moving and confusing moment. By connecting leadership decisions to their downstream consequences, STAT helps readers understand not only what happens inside the FDA but also \u003cem\u003e\u003cstrong\u003ewhat comes next\u003c\/strong\u003e\u003c\/em\u003e.\u003c\/p\u003e\n\u003cp\u003eIf you depend on the FDA’s credibility, whether professionally or personally, this deep dive explains why the agency’s current instability could reshape American medicine for years to come.\u003c\/p\u003e\n\u003cp\u003e\u003ciframe style=\"border: 1px solid #d8dee2; border-radius: 0.5rem; width: 100%; height: 100%; aspect-ratio: 8.5 \/ 11;\" height=\"11\" width=\"8.5\" src=\"https:\/\/embed.documentcloud.org\/documents\/26511211-statnews_fda_report_preview\/?embed=1\"\u003e\u003c\/iframe\u003e\u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":42136964628583,"sku":null,"price":49.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":42136964661351,"sku":null,"price":245.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/2026_FDAReport_MetaImage.png?v=1769709194"},{"product_id":"american-science-shattered","title":"American Science, Shattered","description":"\u003ch2\u003e\u003cb id=\"docs-internal-guid-0df34248-7fff-5e5e-50ab-d62fcb4a49a8\"\u003e\u003cspan\u003eThe definitive account of a system in crisis\u003c\/span\u003e\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eFor decades, the National Institutes of Health has upheld American science. It has been the engine behind breakthroughs in cancer, Alzheimer’s disease, HIV\/AIDS, and countless life-saving therapies. As the world’s largest funder of biomedical research, it helped make the United States the global leader in life sciences. In 2025, that foundation cracked.\u003c\/p\u003e\n\u003ch3\u003eInside the collapse\u003c\/h3\u003e\n\u003cp\u003eThis report is a complete investigative series documenting how the federal government’s sudden policy reversals, grant terminations, and funding cuts upended the social contract between Washington and the nation’s research institutions. The result of this leave scientists and institutions no longer confident in having the federal government as a resolute partner in discovery.\u003c\/p\u003e\n\u003cp\u003eThis report goes far beyond headlines. Nine reporters traveled across the U.S. — and to Europe — to document the human, institutional, and scientific toll.\u003c\/p\u003e\n\u003ch3\u003eWho this report Is for:\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003ePolicymakers and government officials\u003c\/li\u003e\n\u003cli\u003eInvestors in biotech and life sciences\u003c\/li\u003e\n\u003cli\u003eScientists at every career stage\u003c\/li\u003e\n\u003cli\u003ePatient advocates\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003eAnyone interested in the future of American innovation\u003cbr\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003cspan\u003eUnderstand how the Trump administration has disrupted labs, upended lives, and delayed discoveries. \u003c\/span\u003eDownload this report to unpack the definitive, deeply reported account of a year that may reshape U.S. biomedical research for a generation.\u003c\/p\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/27422692-statreport_scienceshattered_2026_preview\/?embed=1\" width=\"8.5\" height=\"11\" style=\"border: 1px solid #d8dee2; border-radius: 0.5rem; width: 100%; height: 100%; aspect-ratio: 8.5 \/ 11\" allow=\"fullscreen\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":42212490575975,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":42212490608743,"sku":null,"price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/2026_ScienceShattered_MetaImage.png?v=1772203007"},{"product_id":"how-ai-is-reshaping-the-flow-of-money-in-health-care","title":"Pay up or payday: How AI is reshaping the flow of money in health care","description":"\u003ch2\u003eAI was supposed to cut health care costs. Instead, it's fueling a billing arms race.\u003c\/h2\u003e\n\u003cp\u003eExplore the hidden financial incentives reshaping medicine's AI revolution and discover who's profiting while patients pay more.\u003c\/p\u003e\n\u003ch3\u003eThe problem with AI in health care\u003c\/h3\u003e\n\u003cp\u003eArtificial intelligence promises infinite abundance in health care: faster diagnoses, better outcomes, lower costs. That's not what's happening. Instead, AI is falling into the blind spots of our fee-for-service system, enabling new ways to game billing codes, and evolving faster than oversight can keep up. The results are technology that often raises costs instead of lowering them, leaving critical questions about patient care unanswered.\u003c\/p\u003e\n\u003ch3\u003eWhat you'll learn:\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eWhy fully approved AI diagnostic tools sit unused because providers can't bill for them and whether fee-for-service codes are the right path forward\u003c\/li\u003e\n\u003cli\u003eHow AI scribes designed to reduce burnout are now mining clinical notes to identify overlooked billing opportunities\u003c\/li\u003e\n\u003cli\u003eWhat happens when insurers deploy AI to speed authorizations during a profit crunch and why providers question their motives\u003c\/li\u003e\n\u003cli\u003eWho's protecting patients as AI enters clinical decisions and medical devices while federal oversight recedes\u003cbr\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThis isn't speculation about AI's future. It's an evidence-based investigation into how AI is reshaping the flow of money in health care right now.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/28039666-statreport-how-ai-is-reshaping-the-flow-of-money-in-health-care-preview\/?embed=1\" width=\"612\" height=\"792\" style=\"border: 1px solid #d8dee2; border-radius: 0.5rem; width: 100%; height: 100%; aspect-ratio: 612 \/ 792;\"\u003e\u003c\/iframe\u003e\u003c\/p\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":42361928253543,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":42361928286311,"sku":null,"price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/2026_AI_in_Health_Care_MetaImage.png?v=1776108674"},{"product_id":"dementia-cares-radical-new-era","title":"Dementia care’s radical new era: The promise and challenges of advances in diagnostics, treatments, and care","description":"\u003ch2\u003e\u003cb id=\"docs-internal-guid-0df34248-7fff-5e5e-50ab-d62fcb4a49a8\"\u003e\u003cspan\u003eDementia care in the age of breakthroughs\u003c\/span\u003e\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eFor decades, dementia was viewed as an inevitable consequence of aging. Remaining difficult to diagnose, impossible to treat, and devastating for patients, families, and health systems alike, but that paradigm is rapidly changing.\u003c\/p\u003e\n\u003ch3\u003eThe future of dementia care is being rewritten\u003c\/h3\u003e\n\u003cp\u003eThis STAT Special Report uses a curated selection articles to examine the breakthroughs, tensions, and emerging strategies reshaping the future of cognitive health. Drawing on deep reporting and expert analysis across medicine, neuroscience, biotechnology, health policy, caregiving, architecture, and technology, the report explores how advances in diagnostics, therapeutics, and care delivery are transforming both clinical practice and the lived experience of dementia.\u003c\/p\u003e\n\u003ch3\u003eInside, readers will gain insight into:\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eThe biomarker revolution redefining how Alzheimer’s disease and related dementias are diagnosed\u003c\/li\u003e\n\u003cli\u003eThe promises and limitations of emerging therapeutics, including amyloid-targeting drugs, AI-enabled tools, and novel approaches under development\u003c\/li\u003e\n\u003cli\u003eHow health systems, emergency departments, and long-term care models are adapting to a rapidly growing patient population\u003c\/li\u003e\n\u003cli\u003eThe role of prevention, public health, and community design in reducing dementia risk across the lifespan\u003c\/li\u003e\n\u003cli\u003eEthical, cultural, and policy questions surrounding autonomy, caregiving, language, and quality of life\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFeaturing commentary from leading clinicians, researchers, technologists, and people living with dementia, this report provides decision-makers with a nuanced understanding of one of the defining health care challenges of the century.\u003c\/p\u003e\n\u003cp\u003eWhether you work in health care, life sciences, policy, digital health, investment, or caregiving, dive into this critical context for understanding where dementia care is headed next and the responsibilities that come with it. Download the report to access forward-looking insights, expert perspectives, and essential reporting on the future of dementia diagnosis, treatment, prevention, and care.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ciframe src=\"https:\/\/embed.documentcloud.org\/documents\/28170001-statnews-special-report-dementia-preview\/?embed=1\" width=\"612\" height=\"792\" style=\"border: 1px solid #d8dee2; border-radius: 0.5rem; width: 100%; height: 100%; aspect-ratio: 612 \/ 792\" allow=\"fullscreen\"\u003e\u003c\/iframe\u003e","brand":"STAT Reports","offers":[{"title":"Individual","offer_id":43785073393767,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true},{"title":"Group","offer_id":43785073426535,"sku":null,"price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0252\/4541\/7575\/files\/2026_DementiaReport_MetaImage.png?v=1779881539"}],"url":"https:\/\/reports.statnews.com\/collections\/frontpage.oembed?page=4","provider":"STAT Reports","version":"1.0","type":"link"}